Eli Lilly’s Diabetes Drug Faces More Shortages as Demand Kicks Up
- Patients are flocking to GLP-1 drugs for weight loss effects
- Four of six dosages of Lilly’s Mounjaro are facing shortages
This article is for subscribers only.
Shortages of Eli Lilly & Co.’s Mounjaro have expanded to include all of the higher doses, showing just how strong demand is for the drug before it even gets formal approval for use in obesity.
Just last month, US regulators said that three of the higher doses of Lilly’s drug were experiencing “intermittent backorders” through July due to increased demand. The latest update adds a fourth dose to that list and extends issues with another, higher-dose option through September, according to a Food and Drug Administration website. Only the two lowest doses of the drug remain fully available.